A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2006
12/28/2006	US20060292202 Drug delivery device
12/28/2006	US20060292201 Methods for the in situ treatment of bone cancer
12/28/2006	US20060292199 PMMA bone cement containing antibiotic/antibiotics
12/28/2006	US20060292194 Treatment for burns and adipose deposits using thyroid hormone compound in a human
12/28/2006	US20060292186 Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
12/28/2006	US20060292185 Topical skin preparations for treatment of skin aging comprising a testosterone ester
12/28/2006	US20060292184 Bioadhesive liquid composition which is substantially free of water
12/28/2006	US20060292183 forming oil in water emulsions containing drugs by heating nanostructure particle size matrices, surfactants and drugs, then cooling while stirring
12/28/2006	US20060292180 Contacting the sample with an isolated antibody specific for an EspA polypeptide, wherein the polypeptide is a secreted protein from enteropathogenic E. coli, detecting binding of the antibody to EspA polypeptide
12/28/2006	US20060292173 Multibacterial vaccines and uses thereof
12/28/2006	US20060292170 Vaccine Composition Against Malaria
12/28/2006	US20060292163 Phytol derived immunoadjuvants and their use in vaccine formulations
12/28/2006	US20060292161 Protective epitopes of adenyl cyclase-haemolysin (AC-Hly), their application to the treatment or to the prevention of bordetella infections
12/28/2006	US20060292158 Method for the treatment of cancer using a novel pharmaceutical composition containing at least one dolastatin 10 derivative
12/28/2006	US20060292151 L-SIGN polymorphisms and methods involving use of same
12/28/2006	US20060292149 antihemophilic factor monoclonal antibodies comprising an immunoglobulin heavy chain and light chain amino acid sequences, with modified by enzymatic deglycosylation or by site directed mutagenesis, used for treating hemostasis disorders; anticoagulants
12/28/2006	US20060292148 Antihuman TNF-alpha antibody activity lowering inhibitor
12/28/2006	US20060292134 Composition for enhancing cellular energy
12/28/2006	US20060292113 Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer
12/28/2006	US20060292112 Dendrimer-photosensitizer complexes for medical applications
12/28/2006	US20060292094 Composition and method of protection against UV irradiation
12/28/2006	US20060292093 Chromen-4-one derivatives
12/28/2006	US20060292086 comprising 0.1 wt. % benzalkonium chloride, 0.12 wt. % dihydroxypropyl PEG-5 linoleammonium chloride, 0.1 wt. % glycereth-2 cocoate, approximately 0.9 wt. % behentrimonium chloride, approximately 0.06 wt. % dihydroxyethyl cocamine oxide, and water; skin sanitizer
12/28/2006	US20060292085 Medicaments
12/28/2006	US20060292083 Inhalation compositions with high drug ratios
12/28/2006	US20060292081 Methods for preparing pharmaceutical compositions
12/28/2006	US20060292080 Vitamin formulation
12/28/2006	US20060292077 Dendritic and star-shaped contrast agents for medical devices and bioabsorbable radiopaque bulk material and method for producing same
12/28/2006	US20060292072 Agents for neutron capture therapy
12/28/2006	US20060289834 External composition containing Unsaturated fatty acid or its salt or ester
12/28/2006	DE4403989B4 Pharmazeutische und/oder kosmetische Zusammensetzung sowie die Verwendung einer derartigen Zusammensetzung Pharmaceutical and / or cosmetic composition and the use of such a composition
12/28/2006	DE29825242U1 A foaming skin cream - contains special additives which make it useful for treating allergies or preventing skin from absorbing carcinogens
12/28/2006	DE202006010725U1 Composition containing modified oligonucleotide with achiral internucleotide phosphate bonds, useful for treating muscular atrophy or promoting muscle growth
12/28/2006	DE10356409B4 Neues Arzneimittel Oxachelin und Derivate New drug Oxachelin and derivatives
12/28/2006	DE102006023178A1 New solid crystalline telmisartan form A useful for preparation of pharmaceutical composition for treatment of hypertension
12/28/2006	DE102005061657A1 Verwendung von substituierten Piperazin- und Morpholinderivaten Use of substituted piperazine and morpholine
12/28/2006	DE102005053679A1 Use of floroquinolones for producing medicament to treat and/or prevent e.g. immunosuppresion, viral and bacterial infections, respiratory tract diseases, digestive tract diseases, and influenza diseases
12/28/2006	DE102005030051A1 New substituted 1-oxo-3,8-diazospiro(4.5)-decan-2-one compounds are 5-hydroxy tryptamine uptake receptor inhibitors, useful to treat and/or prevent e.g. pain, migraine, chronic paroxysomal hemicrania, depression and asthma
12/28/2006	DE102005029126A1 New cripowellin derivatives useful in the preparation of medicament for the treatment of cancer or other proliferative diseases
12/28/2006	DE102005028845A1 New substituted pyrrolidin-2-ones, piperidin-2-ones and isothiazolidine-1,1-dioxides useful for treating e.g. dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, breast cancer and heart failure
12/28/2006	DE102005026061A1 Depolymerisiertes Scleroglucan zur Regulierung und Verbesserung des Feuchtigkeitsgehaltes der Haut Depolymerized scleroglucan for regulating and improving the moisture content of the skin
12/28/2006	DE102005017286B3 Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer Tetrahydronaphthalene derivatives, processes for their preparation and their use as anti-inflammatories
12/28/2006	DE102004063910B4 Trisubstituierte Benzopyranone sowie diese enthaltende Pflanzenextrakte und Mittel Trisubstituted benzopyranones and containing these plant extracts and resources
12/28/2006	CA2850323A1 Methods and compositions involving mirna and mirna inhibitor molecules
12/28/2006	CA2680945A1 Anti-pdgfralpha antibodies
12/28/2006	CA2678008A1 Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies
12/28/2006	CA2655799A1 Thienopyrimidines for pharmaceutical compositions
12/28/2006	CA2646780A1 Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
12/28/2006	CA2633030A1 Intralesional treatment of psoriasis
12/28/2006	CA2613253A1 Combination comprising amino alcohol derivatives as immunosuppressants
12/28/2006	CA2613249A1 Crystals of phenylalanine derivatives, production method thereof and use thereof
12/28/2006	CA2613244A1 Vitreous body visualization agent
12/28/2006	CA2613213A1 Novel compounds of the family of iminosugars, uses thereof for treating lysosomal diseases, and method for preparing same
12/28/2006	CA2613210A1 Multiple sclerosis therapy and diagnosis
12/28/2006	CA2613001A1 Quinoline 3 -sulfonate esters as nk3 receptor modulators
12/28/2006	CA2612941A1 Method for the potentiation of opioid analgesics effects on pain
12/28/2006	CA2612922A1 2-(phenylamino)benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
12/28/2006	CA2612913A1 Cripowellins and synthetic derivatives thereof used as medicaments
12/28/2006	CA2612865A1 Thiazolopyrimidines for the therapy of hyperalgesic pain conditions
12/28/2006	CA2612829A1 Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
12/28/2006	CA2612788A1 Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c
12/28/2006	CA2612770A1 Tumour treatment with gliotoxin derivatives
12/28/2006	CA2612750A1 Method and composition to treat skin ulcers
12/28/2006	CA2612738A1 Solid pharmaceutical composition comprising (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chroman
12/28/2006	CA2612726A1 Halogenated pyrazolo [1,5-a]pyrimidines, processes, uses as gaba-a receptors ligand, compositions and intermediates
12/28/2006	CA2612661A1 Novel thiophene derivatives
12/28/2006	CA2612587A1 Process for preparing amorphous rosuvastatin calcium free of impurities
12/28/2006	CA2612508A1 Treatment of inflammatory conditions
12/28/2006	CA2612495A1 Hexahydro-pyrrolo-isoquinoline compounds for the treatment of cns disorders
12/28/2006	CA2612491A1 Tricyclic opioid modulators
12/28/2006	CA2612451A1 Oxindole derivatives
12/28/2006	CA2612415A1 Estrogen compositions for vaginal administration
12/28/2006	CA2612409A1 Naphthyridine compounds
12/28/2006	CA2612403A1 Antiviral compounds and methods
12/28/2006	CA2612402A1 Formulations comprising fluphenazine or derivatives thereof
12/28/2006	CA2612387A1 Modulators of sperm hypermotility and uses thereof
12/28/2006	CA2612384A1 Nanoparticulate azelnidipine formulations
12/28/2006	CA2612380A1 Estrogen compositions for vaginal administration
12/28/2006	CA2612364A1 Substituted phenylphosphates as mutual prodrugs of steroids and .beta.-agonists the treatment of pulmonary inflammation and bronchoconstriction
12/28/2006	CA2612344A1 Prodrugs of a2b adenosine receptor antagonists
12/28/2006	CA2612333A1 Inhibition of osteolytic lesions by src kinase inhibitors
12/28/2006	CA2612325A1 Chemokine receptor binding compounds
12/28/2006	CA2612315A1 Dosage regimen for prasugrel
12/28/2006	CA2612268A1 Metabolites of 1-[6-(1-ethyl-1-hydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1-yl)-benzyl]-pyrrolidin-2-one as seratonin receptor antagonists
12/28/2006	CA2612265A1 2-substituted benzimidazoles
12/28/2006	CA2612264A1 Heterocyclylaminoalkyl substituted benzimidazoles
12/28/2006	CA2612263A1 1-(2-amino-3-(substituted alkyl)-3h-benzimidazolylmethyl)-3-subtituted-1,3-dihydro-benzoimidazol-2-ones with activity on respiratory syncytial virus
12/28/2006	CA2612262A1 Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases
12/28/2006	CA2612244A1 Methods and reagents for the treatment of inflammatory disorders
12/28/2006	CA2612227A1 Pyrimidine compounds
12/28/2006	CA2612133A1 New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
12/28/2006	CA2612112A1 Process for the production of intermediates for the preparation of tricyclic benzimidazoles
12/28/2006	CA2612109A1 Tricyclic compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists
12/28/2006	CA2612105A1 Chemokine receptor binding compounds
12/28/2006	CA2612090A1 Tablet containing hardly soluble active ingredient
12/28/2006	CA2612079A1 (6-flu0r0-benz0[1,3] dioxolyl)-morpholin-4-yl-methanones and their use as cb1 ligands
12/28/2006	CA2611920A1 Process for preparing pure amorphous rosuvastatin calcium
12/28/2006	CA2611900A1 Benzofuranone derivatives as nonsteroidal progesterone receptor modulators
12/28/2006	CA2611898A1 Pharmaceutical compositions of hops resins
12/28/2006	CA2611897A1 Non-steroidal progesterone receptor modulators

1 ... 3947 3948 3949 3950 3951 3952 3953 3954 3955 3956 3957 3958 3959 3960 3961 3962 3963 3964 3965 3966 3967 ... 7860